Autolus Therapeutics plc announced the appointment of Robert W. Azelby to the Board of Directors. Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to Autolus?s Board. Most recently, Mr. Azelby served as President and Chief Executive Officer of Eliem Therapeutics Inc. Prior to Eliem, he served as the Chief Executive Officer of Alder Bio Pharmaceuticals Inc. from June 2018 until its acquisition by H. Lundbeck A/S in 2019.

Mr. Azelby previously served as Executive Vice President, Chief Commercial Officer of Juno Therapeutics Inc. from 2015 through its acquisition by Celgene in 2018. Earlier in his 15 years at Amgen, Mr. Azelby served in commercial roles including Vice President and General Manager of Amgen Oncology, Vice President of Oncology Sales, Vice President of the Commercial Effectiveness Unit and General Manager of Amgen Netherlands. He currently serves on the Board of Directors at ADC Therapeutics SA and has also served on the Board of Directors of Chinook Therapeutics Inc, Clovis Oncology Inc., Eliem Therapeutics Inc., Alder BioPharmaceuticals Inc., Cascadian Therapeutics Inc., and Immunomedics Inc. He holds a BA in Economics and Religious Studies from the University of Virginia and an MBA from Harvard Business School.